Education
About Us
Working with TipRanks
Follow Us
Eris Lifesciences Ltd (IN:ERIS)
:ERIS
ERIS Stock Chart & Stats
₹1530.85
₹7.70(0.59%)
At close: 4:00 PM EST
₹1530.85
₹7.70(0.59%)
Day’s Range― - ―
52-Week Range₹1,187.10 - ₹1,909.55
Previous CloseN/A
Volume91.31K
Average Volume (3M)2.07K
Market Cap
₹185.27B
Enterprise Value₹208.45B
Total Cash (Recent Filing)₹2.05B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)51.4
Beta0.63
Next Earnings
May 26, 2026EPS Estimate
11.7Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)7.30
Shares Outstanding136,216,890
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio-5.23
Price to Book (P/B)6.64
Price to Sales (P/S)6.58
P/FCF Ratio20.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)42.7
Revenue Forecast (FY)₹32.02B
Bulls Say, Bears Say
Bulls Say
Revenue & Cash Flow GrowthSustained revenue and operating cash flow growth indicates the business can generate internal funding for marketing, product launches and working capital. Over a 2–6 month horizon this underpins reinvestment capacity, supports margins and reduces reliance on external financing.
Balance Sheet StrengthA solid equity base and manageable debt-to-equity imply financial resilience and flexibility to fund growth or withstand shocks. This structural strength supports strategic choices—M&A, steady capex, or sales investment—without materially increasing leverage in the near term.
Branded Chronic-Focused Business ModelConcentration on branded chronic therapies (cardiometabolic, diabetes, CVD) and a physician-facing sales network creates recurring demand and high brand stickiness. Chronic segments drive predictable prescription volumes and revenue durability over several months to years.
Bears Say
Declining Cash BalancesA declining cash balance reduces the company’s short-term liquidity cushion and flexibility to absorb shocks or accelerate strategic initiatives. Over a 2–6 month timeframe this could constrain discretionary spending or require higher reliance on working capital management or external funding.
Free Cash Flow VolatilityMaterial swings in free cash flow create uncertainty for capex planning, dividend/distribution policies and provisioning for promotional spend. Persistent volatility complicates multi-quarter planning and could force more conservative investment or holdbacks during weaker cash periods.
Exposure To Price-Control & Prescriber AcceptanceRevenue and margin durability depend on prescriber adoption and an Indian regulatory environment that can impose price controls. Structural changes to pricing policy or weaker brand uptake could materially compress margins and growth prospects across several months to years.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1187.10 and its highest was ₹1909.55 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹185.27B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is May 26, 2026 which is in 78 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Feb 13, 2026. The company reported ₹7.3 earnings per share for the quarter, missing the consensus estimate of ₹9.625 by -₹2.325.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 11.7.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 136,216,890 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹7.3 in its last earnings report, missing expectations of ₹9.625. Following the earnings report the stock price went down -6.38%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi Consumer Healthcare India Limited
―